Nasdaq 100 Falls as Hot PCE Inflation Stirs Rate-Hike Bets: Stock Market Today
Nasdaq 100 falls 0.6% as traders wait on Nvidia and hot July PCE revives September rate-hike bets. Energy leads, gold sinks 1.3% to $4,599.
Read original at benzingaStocks · News reference
Jim Cramer: Arista Is ‘Terrific,’ Also Likes This Consumer Cyclical Stock
Jim Cramer likes Ross Stores (ROST) on CNBC's Mad Money Lightning Round. Ross Stores reported strong earnings and raised guidance. Arista Networks (ANET) is also favored.
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Jul 29, 2026, 12:12 PM
- Checked
- Jul 29, 2026, 12:12 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Arista Networks vs. Palantir Technologies: Which Technology Stock Is a Better Buy in 2026?
Arista Networks and Palantir Technologies represent two different paths in the AI and data infrastructure space. Arista provides high-speed networking hardware with strong fundamentals (39% net margins, zero debt, $4.3B free cash flow) but trades at 50.6x forward P/E. Palantir offers data analytics software with accelerating growth (93% YoY revenue growth, mid-50s net margins) but commands a premium 112.7x forward P/E. While Palantir's recent performance strengthens its valuation case, Arista remains the steadier, more conventionally attractive investment for risk-averse investors.
Read original at the-motley-foolEli Lilly Announces Results From Real-World Study Of Overweight Or Obese Adults Over 55 Indicating That Staying On Zepbound For Weight Management Lowered Healthcare Costs Over Time
For adults over the age of 55, including patients in Medicare's GLP-1 Bridge program, these lower costs translate into meaningful savings as early as 12 months into treatment. This is the first study of its kind in
Read original at benzingaTruist Securities Maintains Hold on Hims & Hers Health, Raises Price Target to $32
Truist Securities analyst Jailendra Singh maintains Hims & Hers Health (NYSE:HIMS) with a Hold and raises the price target from $27 to $32.
Read original at benzingaBarclays Maintains Overweight on Hims & Hers Health, Lowers Price Target to $35
Barclays analyst Glen Santangelo maintains Hims & Hers Health (NYSE:HIMS) with a Overweight and lowers the price target from $39 to $35.
Read original at benzingaHims & Hers Rejects Privacy Allegations While Promising Expanded Patient Access
Hims & Hers CEO Andrew Dudum defends the firm against an FTC lawsuit, discusses dropping GLP-1 drug prices and reveals in-house AI plans.
Read original at benzinga